Weng, Z., Ertle, J., Zheng, S., Lauenstein, T., Mueller, S., Bockisch, A., Gerken, G., Yang, D. and Schlaak, J.F. (2013) A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization. PLoS ONE, 8, e82225.
https://doi.org/10.1371/journal.pone.0082225

has been cited by the following article:

• TITLE: Outcome Results of Treatment with Selective Internal Radiation Therapy (SIRT) in Patients with Hepatocellular Carcinoma: A Single Center Experience

  AUTHORS: Jan Pfeiffenberger, Tatjana Zimmermann, Daniel N. Gotthardt, Christoph Springfeld, Wolfgang Stremmel, Peter Schirmacher, Henning Schulze-Bergkamen, Arianeb Mehrabi, Christoph W. Michalski, Katrin Hoffmann, Nikolas Kortes, Boris Radeleff, Uwe Haberkorn, Clemens Kratochwil, Karl Heinz Weiss, Carsten Grüllich

  KEYWORDS: SIRT, Sorafenib, Liver Cancer, Y90

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.4, April 28, 2017

  ABSTRACT: Background: Hepatocellular carcinoma (HCC) has a poor prognosis. Selective internal radiation therapy (SIRT) with microspheres is a treatment option for HCC. This study aimed to assess safety and survival (OS) in patients with HCC treated with SIRT, to stratify patients with tumor vascularization and analyze the impact of sequential sorafenib treatment. Methods: Thirty-nine patients who received SIRT for HCC between 2010 and 2013 at our center were included in this retrospective analysis. Tumor vascularization was assessed using a combination of MRI, MAA-scintigraphy and angiography. Tumor vascularization was correlated with survival. Subgroups are treated with two commercially available 90Y-labeled products SIR-Spheres (n = 16) and TheraSpheres (n = 23) and sequential therapy with sorafenib compared to SIRT only was analyzed. Results: Adverse events occurred in 49% of patients with only four grade 3 and no grade 4 event. Median survival for all patients was 12.5 months (95% CI: 8.7 - 16.3). No significant differences were detectable between Thera Spheres or SIR Spheres. Survival was shorter in patients with low tumor vascularization score (OS: 3.8 months (95% CI 0 - 15.0), p = 0.043). Survival was longer with sorafenib upon progression after SIRT (n=16) with an OS of 17.4 months (95% CI: 12.1 – 22.7) compared to no sorafenib (n = 13; 9.1 months; 95% CI: 3.0 - 15.1) or progression upon sorafenib before SIRT (n = 10; 8.6 months; 95% CI: 5.5 - 11.7). Conclusions: SIRT is safe in HCC patients. Tumor vascularization by radiography and scintigraphy may predict survival benefit. Sorafenib is active after SIRT and significantly prolongs survival.